Table 1.

Characteristics of calciphylaxis cases and controls

	Age, years	Gender	Race	ESRD	ESRD duration, months	Diabetes mellitus	Serum calcium, mg/dL	Serum phosphate, mg/dL	Serum parathyroid hormone, pg/mL	Warfarin
Cases
1	44	Female	White	Yes	34	No	10.6	6.1	287	No
2	69	Female	White	Yes	29	Yes	9.7	3.5	129	Yes
3	66	Male	White	Yes	10	Yes	9.6	3.2	151	Yes
4	55	Male	White	Yes	151	No	8.6	4.6	2,140	Yes
5	57	Female	Black	Yes	72	No	10.4	5.5	510	Yes
6	48	Female	Black	Yes	5	Yes	8.1	2.3	226	No
7	59	Female	White	Yes	159	Yes	9.0	3.6	624	No
8	78	Male	Black	Yes	67	No	8.7	6.2	235	Yes
9	59	Female	Black	Yes	48	Yes	8.5	3.5	720	Yes
10	65	Male	White	Yes	43	No	10.7	3.4	341	Yes
11	63	Female	White	No	Not applicable	No	9.4	3.9	31	No
12	55	Male	White	No	Not applicable	No	9.8	3.8	61	No
13	66	Male	White	Yes	21	No	9.7	3.8	100	No
14	56	Male	White	No	Not applicable	Yes	9.0	5.2	58	Yes
15	68	Male	White	Yes	60	Yes	9.5	3.5	145	No
16	44	Female	White	Yes	112	Yes	9.9	5.8	57	Yes
17	49	Male	White	Yes	4	Yes	9.6	3.8	75	No
18	64	Female	White	Yes	45	Yes	10.3	4.7	513	Yes
Controls
1	58	Female	White	No	Not applicable	No	9.6	3.3	Not available	No
2	44	Female	White	No	Not applicable	No	9.5	2.8	Not available	No
3	41	Female	White	No	Not applicable	No	9.1	2.5	145	No
4	59	Male	White	Yes	60	Yes	8.1	6.1	694	Yes
5	60	Female	White	Yes	234	No	8.3	3.1	196	No
6	57	Female	White	Yes	56	Yes	9.9	4.4	463	No
7	43	Female	White	Yes	3	No	10.1	3.3	679	Yes
8	62	Male	White	Yes	58	No	9.7	6.0	872	No
9	42	Female	White	Yes	49	No	10.2	4.5	342	No
10	64	Female	White	Yes	31	No	11.9	5.8	130	No
11	65	Male	White	Yes	84	Yes	9.7	3.4	1,512	No
12	86	Male	White	No	Not applicable	No	9.3	3.1	27	Yes

ESRD, end-stage renal disease.